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Dr Patrick McCarthy (Chicago, Ill). By disclosure, I am
a coinventor of the IMR ETlogix ring (Edwards Lifesciences,
Irvine, Calif).
Congratulations, Dr Maltais, on an excellent and timely presen-
tation. We look forward to the results of the ongoing National1000 The Journal of Thoracic and Cardiovascular SurInstitutes of Health prospective randomized trial that will give fur-
ther information on this important subject.
As you note, patient factors were important to survival, but we
can’t modify those. As surgeons, we can decide, however, between
MVR and MVP. So I have questions about how that decision was
made and late outcomes.
First, can you provide insight into why MVR was sometimes
chosen?Was it influenced by the degree of leaflet tethering or other
factors seen on echocardiography? Was MVR used for worse ven-
tricles or more complex and extensive MR? Others have found no
difference in survival between MVP and MVR in single-center
studies, but did you look at other outcomes, such as need for trans-
plant or ventricular assist device, late New York Heart functional
class, and rehospitalization for cardiac cause, and do you have
any data on late MR recurrence? Finally, after this study, what
do you do now, repair or replace?
DrMaltais.Regarding your first question, this is a retrospective
study with all the biases that it implies. I would say that in our cen-
ter, the most important thing is to achieve a complete repair, and all
the patients are leaving the operating room with trivial MR. That
being said, one could argue that when a patient presents with
a heavy ischemic burden, one will be more inclined to repair the
valve, compared with a patient who presents with an extremely
dilated LV or lots of tethering, where surgeons might be more
inclined to replace the valve. This is, however, certainly a good
question, and it warrants prospective randomized studies to
answer.
In regard to your second question, as you pointed out, lots of
studies have shown that these patients are really sick, especially
the subgroup with low ejection fractions. We don’t have the inci-
dence of ventricular assist device or heart transplantation in this
population because this is a retrospective study. Furthermore, we
don’t have the incidence of late recurrence of MR or readmission
for symptomatic heart failure.
However, in regard to ventricular assist device or heart trans-
plantation, we are certainly looking at this population of sick
patients, and we believe there might be a subgroup of patients
with poor targets for bypasses who could be candidates for
these advanced heart failure therapies even as a first option of
treatment.
In regard to MR recurrence, although all those patients are leav-
ing the operating room with trivial MR, we know the amount of
recurrence of MR is approximately 20% to 30%. This can influ-
ence a surgeon’s decision to replace or repair the valve initially ac-
cording to the patient’s symptoms. If the patient presents with
severe angina symptoms, the most important thing is to perform
CABG, but if the patient presents with long-term congestive heart
failure symptoms, the most important thing is to have no recur-
rence of MR. This might influence the surgeon’s decision.
Dr McCarthy. What would you do now?
Dr Maltais. This is a simple study that has shown us that when
we look at the overall population, the type of procedure didn’t
seem to influence the overall survival. This study was intended
to be simple, to look at what is really important in this population.
From these results, the most important aspect seems to be patient
selection. If the patient has anMVP, it has to be quick and efficient.
Only the underlying patients’ condition and presentation at the
time of surgery seem to influence survival.gery c November 2011
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DDr Ottavio Alfieri (Milan, Italy). May I ask which kind of
repair you carried out?
DrMaltais. This is it. A retrospective study, but more than 90%
of those patients had an undersized ring. Patients with mixed dis-
ease are a little harder to analyze, but all those patients had IMR,
and neochordae and leaflet resection were the most frequent con-
comitant techniques used.
Dr Robert Dion (Genk, Belgium). I would like to return to the
technique. When you repair the valve, do you use a complete,
pliable, or rigid ring? If you undersize, when and how much do
you undersize?
Dr Maltais. With regard to the type of repair, the numbers are
small when we looked at subgroups, but the type of ring did not
change results. Most of the surgeons try to undersize 2 sizes.
Dr Dion. If you replace the valve, do you systematically use
a bioprosthesis, and if you use a bioprosthesis, what sizing are
you applying? Are you aiming at the largest possible size or trying
to somewhat shrink the base of the heart by using some undersiz-
ing? What is the policy?
Dr Maltais. We don’t have any policy to look at those results
specifically. In patients with replacement, all had preservation of
the posterior mitral apparatus, and we believe this is the most
important thing.
Dr Paul Kurlansky (Miami, Fla). Very interesting and provoc-
ativework. As you probably know, there are emerging data on IMR
that although the patients with MR have a worse prognosis, it
doesn’t necessarily seem to matter whether or not you repair/
replace the valve in terms of their long-term survival. So in view
of that, I was just wondering what exactly are your indications
for surgically addressing the MV?
Dr Maltais. Patients with moderate IMR are another topic. But
these are all patients who needed to have a procedure performed on
the MV, and therefore all patients had more than moderate MR. If
repair is possible, this is the procedure of choice.
Dr Thierry Mesana (Ottawa, Ontario, Canada). A great
study, Simon, and great results. We actually presented the
same study with propensity case matching at the Society of
Thoracic Surgeons. First, in your population with MVP, you
had a high number of patients with redos, were these patients
with previous MVR? Second, did you look at the LV function
in both groups? Did you see a difference in recovery of LV func-
tion with one or the other group and eventually LV size changes
after the LV repair versus replacement?
Dr Maltais. In terms of MVR, most of the patients with a pre-
vious MVP had MVR. This was a retrospective study, again, andThe Journal of Thoracic and Carthe hard thing to point out is how many patients had replacement
because they had 1 or 2 failed attempts to repair.
In terms of recurrence of MR and LV remodeling, this is some-
thing we are looking into. Approximately 20% to 30% of those pa-
tients will have recurrence of MR, which reflects the underlying
disease and ventricular problem. In further studies, we will be
looking into LV dimension reduction or recuperation of LV func-
tion as a potential marker of survival in patients with recurrent
MR.
Dr Mesana. A great study, and actually we had presented sim-
ilar results, including the recurrence of MR, which did not affect
long-term survival.
Dr Maltais. Thank you.
Dr Steven Bolling (Ann Arbor, Mich). Simon, a very nice study.
You don’t have long-term echocardiography follow-up on these
patients, is that correct?
Dr Maltais. We do have echocardiography follow-up on those
patients but with midterm follow-up.
Dr Bolling. So then, I will ask you in a different way. Is it pos-
sible that on your curve you actually have 3 groups, good mitral
repair, mitral replacement, and bad mitral repair, meaning a bunch
of patients who had recurrence. Could it be you are not really look-
ing at MVP versus MVR, but whether the patients have recurrent
MR in one group and not in another and whether they were able to
remodel their ventricles. Do you have enough data and follow-up
echocardiography to say that?
Dr Maltais. At this point, I would say we don’t. We are cur-
rently looking at those data and trying to assess this more in detail.
Themain advantage ofMVR compared withMVP is obviously the
fact that all those patients don’t have recurrentMR. As you pointed
out, there might be a subgroup of patients with recurrent MR with
a higher mortality compared with patients with perfect repairs and
MVR.
Dr Soon Park. I think we need to separate a few things out for
discussion. The National Heart, Lung, and Blood Institute Cardio-
thoracic Surgical Trial Network study may inform us about what
might happen to the LV geometry after repair versus replacement,
but it probably will not tell us much about survival. The current
study is a retrospective review, and its primary focus is on survival.
We really do not know how recurrent MR might affect survival or
the impact of MVR, whether it has a significant adverse impact or
not. Clearly, we need to study these issues further in the future.
Meanwhile, this study seems to illustrate important factors that in-
fluence the outcome after surgery in this high-risk group, and it
seems that MVR versus MVP does not make a difference.diovascular Surgery c Volume 142, Number 5 1001
